HEAD-TO-HEAD

THYMOSIN α-1 VS BPC-157

Thymosin alpha-1 and BPC-157 are commonly co-mentioned in recovery and immune research, but they target completely different systems. Thymosin alpha-1 (Tα1, Zadaxin) is a 28-aa thymic immunomodulator (TLR9 agonism, T-cell + NK-cell activation) approved in 35+ countries for chronic hepatitis B/C. BPC-157 is a 15-aa gastric-origin pentadecapeptide acting through VEGF / NO / GHR upregulation for connective-tissue cytoprotection. Immune vs regen.

A · No. 026

THYMOSIN α-1

TA-1 · Zadaxin · Immune Modulator

B · No. 003

BPC-157

Pentadecapeptide Cytoprotection

SIDE BY SIDE

FIELD

A · THYMOSIN α-1

B · BPC-157

Class

Synthetic 28-aa thymic peptide · immunomodulator

Synthetic 15-aa peptide (gastric-origin fragment)

Sequence

28-aa thymalfasin · Ac-Ser-Asp-Ala...Asn

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

Mechanism

TLR9 agonism · dendritic-cell maturation · T-cell + NK-cell activation · Th1 bias

VEGF / NO / GHR upregulation · cytoprotection paradigm

Half-life

~2 hours plasma (subcutaneous)

~4 hours (rat, intraperitoneal)

Primary research focus

Chronic hepatitis B/C · sepsis (ETASS) · immunocompromised support · COVID-19

GI mucosal protection · tendon-ligament healing

Best published evidence

Multiple Phase 3 trials supporting Zadaxin approval; Wu 2013 Crit Care sepsis trial PMID 23327199

Sikiric multi-paper rodent literature; Krivic 2006 PMID 16583442 tendon

FDA status

Not FDA-approved in US · approved as Zadaxin in 35+ countries

FDA Cat 2 503A bulks list (Sept 2023) · research-use only

WADA status

Not currently listed (2026)

Prohibited at all times (S0)

WHICH IS BETTER · BY GOAL

▶ Immune-system / antiviral researchA · THYMOSIN α-1

Thymosin alpha-1 has the Zadaxin Phase 3 program in hepatitis B/C and multi-country approved indication. BPC-157 is not framed as an antiviral or immune-modulator.

▶ Tendon / ligament / wound researchB · BPC-157

BPC-157 has the Sikiric multi-paper rodent evidence base for tendon, ligament, and gastric repair. Thymosin alpha-1 is not specifically studied in connective-tissue healing.

▶ Sepsis / critical-care researchA · THYMOSIN α-1

Wu 2013 (Crit Care, PMID 23327199) reported 28-day mortality reduction in severe sepsis with Tα1. BPC-157 not specifically studied in sepsis.

▶ GI mucosal protection researchB · BPC-157

BPC-157's gastric-cytoprotection signature is the canonical evidence base. Tα1 not specifically studied in GI mucosa.

▶ Approved-product clinical evidence baseA · THYMOSIN α-1

Thymosin alpha-1 is approved as Zadaxin in 35+ countries. BPC-157 has no approved human indication anywhere.

STACKING NOTE

Thymosin alpha-1 + BPC-157 covers two non-overlapping research axes (immune system + connective-tissue cytoprotection). No published RCT validates the combination, but mechanistic complementarity is the basis for community-protocol framings around recovery + immune support.

SOURCED FROM GIGACOMPOUNDS

Both compounds are available as research-grade material at GigaCompounds · ≥99% purity · per-batch CoA. For laboratory research use only.

SOURCE AT GIGACOMPOUNDS ▶